Drugs / MEDI2228
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03489525 | May 2018 → Mar 2022 | refractory plasma cell neoplasm | MedImmune LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | AstraZeneca | Results AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020 astrazeneca.com ↗
First-in-human data from the potential new medicine B-cell maturation antigen (BCMA)-targeted antibody drug conjugate, MEDI2228, presenting data on safety and efficacy at all dose levels in relapsed or refractory multiple myeloma |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | AstraZeneca | AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020 astrazeneca.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI2228 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03489525 ↗ |